According to a press release by the U.S. Headquarters in Cambridge, Massachusetts for Biogen Idec, Friday was a momentous day for those suffering with Relapsing Multiple Sclerosis, as approval has been given by the FDA and Plegridy is scheduled to be available within the next few months.
Soon, there will be a subcutaneous drug to take at home every two weeks, instead of daily or three times a week. Plegridy is a peginterferon beta-1a drug, to be available in a 125 mcg. pen or prefilled syringe.
In order to acclimate the body to Plegridy, the first two injections are of lower dosages. The patient prescribed the drug will receive a starter kit. This kit includes a first dosage of 63 mcg. on day one and two weeks after the first dose, a dosage of 94 mcg. will be administered on day fifteen. Both starter packs are available in prefilled syringe and the Plegridy Pen.
, for Biogen Idec is dedicated to the treatment of multiple sclerosis, and other devastating and difficult to treat diseases like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. They are the leader in multiple sclerosis research, and developed the leading oral multiple sclerosis drug in Tecfidera; the leading interferon based therapy in Avonex and, now the first twice monthly interferon drug for the treatment of MS in Plegridy. They also developed the first significant advances in hemophilia A and hemophilia B in fifteen years.
As with any drug, there are side effects, which must be taken into consideration and a list is located on the Plegridy home page.